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Supplementary Table S1: Cox-regression model for Overall Survival in the training cohort. 
Parameters Univariable Multivariable (n=304 patients 
with all tested variables 
available) 
HR (95% CI) P HR (95% CI) P 
Age (continuous) (n=370) 1.0 (0.98-1.01) P =0.39   
Gender (Female vs Male) 
(n=370) 
0.87 (0.57-1.31) P =0.49   
Cirrhosis (Present vs 
absent) (n=306) 
1.17 (0.89-1.54) P =0.27   
Albumin: 
- continuous 































Previous Treatment for 
HCC (Yes vs No) 
(n=306) 
0.74 (0.58-0.94) P =0.012 NS NS 
Performance status (>0 vs 
0) 
(n=368) 
1.64 (1.31-2.04) P <0.001 1.82 (1.40-2.37) P <0.001 
Size of the largest liver 
lesion: 
- continuous 




















(Present vs absent) 
(n=360) 
1.02 (0.81-1.28) P =0.88   
Portal vein 
thrombosisMacrovascular 
invasion (Present vs 
absent) 
(n=359) 



















Supplementary Table S2: Survival according to different scores. 
 n in each 
class 











     
SAP A 109 
(30.1%) 
14.9 months [95% 
CI: 10.9-18.8] 
86% 59% 31% 
SAP B 191 
(52.8%) 
7.2 months [95% CI: 
6.3-8.1] 
59% 32% 12% 
SAP C 62 
(17.2%) 
2.5 months [95% CI: 
1.6-3.3] 
23% 13% 5% 
Validation cohort 
(n=468) 
     




83% 59% 39% 




61% 37% 16% 




26% 15% 2% 




77% 50% 32% 




54% 34% 13% 
ALBI grade 3 26 (5.6%) 2.1 months [0.7-
3.5] 
29% 25% 15% 




83% 71% 39% 




59% 35% 18% 
BCLC D 4 (0.9%) 1.5 months [0.6-
2.4] 
NA NA NA 




86% 60% 44% 




74% 50% 28% 




79% 54% 34% 




58% 34% 13% 




27% 15% 2% 
Validation cohort 
“Best candidates”: 
     
Child Pugh A, BCLC B 
or C (n=356) 




85% 62% 40% 




65% 39% 16% 
SAP C 35 (9.8%) 4.5 months [3.2-
5.8] 
31% 16% 0% 




79% 52% 33% 




60% 39% 14% 
ALBI grade 3 0 (0%)     




84% 74% 38% 




66% 41% 22% 
BCLC D 0 (0.0%)     




89% 65% 47% 




75% 52% 28% 




81% 57% 36% 




61% 35% 11% 




35% 19% 0% 
  
Supplementary Table S3: Comparison of the results of the worse class of each score in the 
validation cohort. 





AUC 6 month 12-
months 
survival 

















HAP D 92 (19.7%) 3.8 months [3.4-
4.2] 
27% 0.644 [0.603-
0.685] 
15% 
 
